$SESN so the scoreboard is Vicinium is tasked by FDA to expand its label to patients with less than adequate BCG while Instilladrin runs phase 3 through 3rd QTR 2022 on BCG unresponsive NMIBC patients following bullish results on BCG refractory patients (the easier to treat patients) in ph 1&2. Even with possible trip to market the instilladrin label doesn’t expand to Sesen’s market until at the very least 2023. Correct me if I have any errors here but this is my current understanding of the situation
  • 4
  • 1